Originally published as JCO Early Release 10.1200/JCO.2008.20.8397 on December 29 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bokemeyer, C. Articles by Koralewski, P. Search for Related Content PubMed PubMed Citation Articles by Bokemeyer, C. Articles by Koralewski, P. Related Articles Related Article Related Editorial Social Bookmarking                            What's this?

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

From the University Hospital, Hamburg-Eppendorf; South West German Comprehensive Cancer, University Hospital Tübingen, Tübingen; Merck Serono, Darmstadt Germany; State Medical Academy, City Clinical Hospital #4, Dnepropetrovsk, Ukraine; Moscow City Oncology Hospital #62, Moscow Area, Russian Federation; Hospital Universitario La Fe, Valencia, Spain; Istituto Europeo di Oncologia, Milan, Italy; Institutul Oncologic "Prof. Dr. Al. Trestioreanu" Bucuresti, Bucharest, Romania; Wilhelminenspital der Stadt Wien, Vienna, Austria; and Wojewódzki Szpital Specjalistyczny Oddzia Chemioterapii, Krakow, Poland.

Corresponding author: Carsten Bokemeyer, MD, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg-Eppendorf, Germany; e-mail: c.bokemeyer{at}uke.uni-hamburg.de.

Purpose This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer. The influence of KRAS mutation status was investigated.

Patients and Methods Patients received cetuximab (400 mg/m² initial dose followed by 250 mg/m²/wk thereafter) plus FOLFOX-4 (oxaliplatin 85 mg/m² on day 1, plus leucovorin 200 mg/m² and fluorouracil as a 400 mg/m² bolus followed by a 600 mg/m² infusion during 22 hours on days 1 and 2; n = 169) or FOLFOX-4 alone (n = 168). Treatment was continued until disease progression or unacceptable toxicity. KRAS mutation status was assessed in the subset of patients with assessable tumor samples (n = 233).

Results The confirmed ORR for cetuximab plus FOLFOX-4 was higher than with FOLFOX-4 alone (46% v 36%). A statistically significant increase in the odds for a response with the addition of cetuximab to FOLFOX-4 could not be established (odds ratio = 1.52; P = .064). In patients with KRAS wild-type tumors, the addition of cetuximab to FOLFOX-4 was associated with a clinically significant increased chance of response (ORR = 61% v 37%; odds ratio = 2.54; P = .011) and a lower risk of disease progression (hazard ratio = 0.57; P = .0163) compared with FOLFOX-4 alone. Cetuximab plus FOLFOX-4 was generally well tolerated.

Conclusion KRAS mutational status was shown to be a highly predictive selection criterion in relation to the treatment decision regarding the addition of cetuximab to FOLFOX-4 for previously untreated patients with metastatic colorectal cancer.

Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; 14th European Cancer Conference, September 23-27, 2007, Barcelona, Spain; 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL; and The ESMO International Symposium: 10th World Congress on Gastrointestinal Cancer, June 25-28, 2008, Barcelona, Spain.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on JCO.org.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Article

• A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
  J. Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David Spigel, John Marshall, Allen Cohn, David McCollum, Philip Stella, Robert Deeter, Seta Shahin, and Rafael G. Amado
  JCO 2009 27: 672-680 [Abstract] [Full Text]

Related Editorial

• Dual-Antibody Therapy in Advanced Colorectal Cancer: Gather Ye Rosebuds While Ye May
  Charles D. Blanke
  JCO 2009 27: 655-658 [Full Text]

This article has been cited by other articles:

				N. Boku Current Status and Problems in Development of Molecular Target Agents for Gastrointestinal Malignancy in Japan Jpn. J. Clin. Oncol., January 4, 2010; (2010) hyp171v1. [Abstract] [Full Text] [PDF]

				C. Eng The Evolving Role of Monoclonal Antibodies in Colorectal Cancer: Early Presumptions and Impact on Clinical Trial Development Oncologist, January 1, 2010; 15(1): 73 - 84. [Abstract] [Full Text] [PDF]

				M. S. Banck and A. Grothey Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer Clin. Cancer Res., December 15, 2009; 15(24): 7492 - 7501. [Abstract] [Full Text] [PDF]

				S. Ogino, J. A. Meyerhardt, N. Irahara, D. Niedzwiecki, D. Hollis, L. B. Saltz, R. J. Mayer, P. Schaefer, R. Whittom, A. Hantel, et al. KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803 Clin. Cancer Res., December 1, 2009; 15(23): 7322 - 7329. [Abstract] [Full Text] [PDF]

				J. Tabernero, F. Ciardiello, F. Rivera, E. Rodriguez-Braun, F. J. Ramos, E. Martinelli, M. E. Vega-Villegas, S. Rosello, S. Liebscher, O. Kisker, et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study Ann. Onc., November 25, 2009; (2009) mdp549v1. [Abstract] [Full Text] [PDF]

				S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer J Natl Cancer Inst, October 7, 2009; 101(19): 1308 - 1324. [Abstract] [Full Text] [PDF]

				N. Damjanov, J. Weiss, and D. G. Haller Resection of the Primary Colorectal Cancer Is Not Necessary in Nonobstructed Patients with Metastatic Disease Oncologist, October 1, 2009; 14(10): 963 - 969. [Abstract] [Full Text] [PDF]

				T. Fojo and C. Grady How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question J Natl Cancer Inst, August 5, 2009; 101(15): 1044 - 1048. [Abstract] [Full Text] [PDF]

				H. Spiro, F. Roila, M. C. Garassino, E. Ballatori, E. Bria, F. Cuppone, M. Di Maio, S. Garattini, V. Torri, I. Floriani, et al. Cetuximab for metastatic colorectal cancer. N. Engl. J. Med., July 2, 2009; 361(1): 95 - 96. [Full Text] [PDF]

				E. Van Cutsem, R. Labianca, G. Bodoky, C. Barone, E. Aranda, B. Nordlinger, C. Topham, J. Tabernero, T. Andre, A. F. Sobrero, et al. Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3 J. Clin. Oncol., July 1, 2009; 27(19): 3117 - 3125. [Abstract] [Full Text] [PDF]

				P. R. Pohlmann, R. L. Mernaugh, L. W. Goff, L. Frati, G. Codacci-Pisanelli, M. S. Copur, M. Norvell, A. Obermiller, F. Loupakis, M. Di Maio, et al. Chemotherapy and Immunotherapy in Metastatic Colorectal Cancer N. Engl. J. Med., May 14, 2009; 360(20): 2134 - 2136. [Full Text] [PDF]

				E. Van Cutsem, C.-H. Kohne, E. Hitre, J. Zaluski, C.-R. Chang Chien, A. Makhson, G. D'Haens, T. Pinter, R. Lim, G. Bodoky, et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer N. Engl. J. Med., April 2, 2009; 360(14): 1408 - 1417. [Abstract] [Full Text] [PDF]

				C. D. Blanke Dual-Antibody Therapy in Advanced Colorectal Cancer: Gather Ye Rosebuds While Ye May J. Clin. Oncol., February 10, 2009; 27(5): 655 - 658. [Full Text] [PDF]